Below are the most recent publications written about "Everolimus" by people in Profiles.
-
Nghiemphu PL, Vitte J, Dombi E, Nguyen T, Wagle N, Ishiyama A, Sepahdari AR, Cachia D, Widemann BC, Brackmann DE, Doherty JK, Kalamarides M, Giovannini M. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. J Neurooncol. 2024 Apr; 167(2):339-348.
-
da Silva-Oliveira RJ, Gomes INF, da Silva LS, Lengert AVH, Laus AC, Melendez ME, Munari CC, Cury FP, Longato GB, Reis RM. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. Int J Mol Sci. 2022 Jul 14; 23(14).
-
Guedeney P, Claessen BE, Mehran R, Kandzari DE, Aquino M, Davis S, Tamis L, Wang JC, Othman I, Gigliotti OS, Haghighat A, Singh S, Lopez M, Giugliano G, Horwitz PA, Sorrentino S, Underwood P, Allocco D, Meredith IT, Batchelor W. Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies. Catheter Cardiovasc Interv. 2019 Jul 01; 94(1):82-90.
-
Batchelor W, Kandzari DE, Davis S, Tami L, Wang JC, Othman I, Gigliotti OS, Haghighat A, Singh S, Lopez M, Giugliano G, Horwitz PA, Chandrasekhar J, Underwood P, Thompson CA, Mehran R. Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation: Insights and Results From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study Pooled Analysis. JAMA Cardiol. 2017 Dec 01; 2(12):1303-1313.
-
Rahban Y, Kimmelstiel C. Real life experience with bioresorbable-polymer everolimus-eluting stents. Is this an answer in search of a question? Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):888-889.
-
Teeuwen K, Spoormans EM, Bennett J, Dubois C, Desmet W, Ughi GJ, Belmans A, Kelder JC, Tijssen JGP, Agostoni P, Suttorp MJ, Adriaenssens T. Optical coherence tomography findings: insights from the "randomised multicentre trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions" (PRISON IV) trial. EuroIntervention. 2017 Aug 04; 13(5):e522-e530.
-
Dubois C, Bennett J, Dens J, De Cock D, Desmet W, Belmans A, Ughi GJ, Sinnaeve P, Vrolix M, D'hooge J, Adriaenssens T. COmplex coronary Bifurcation lesions: RAndomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial. EuroIntervention. 2016 Apr 20; 11(13):1457-67.
-
Adriaenssens T, Ughi GJ, Dubois C, De Cock D, Onsea K, Bennett J, Wiyono S, Sinnaeve P, Coosemans M, Ferdinande B, Belmans A, D'hooge J, Desmet W. STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus vs. biolimus A9-eluting stent implantation): a randomised controlled trial. EuroIntervention. 2016 Apr 08; 11(14):e1619-26.
-
Karam S, Wali RK. Current State of Immunosuppression: Past, Present, and Future. Crit Rev Eukaryot Gene Expr. 2015; 25(2):113-34.
-
Adriaenssens T, Dens J, Ughi G, Bennett J, Dubois C, Sinnaeve P, Wiyono S, Coosemans M, Belmans A, D'hooge J, Vrolix M, Desmet W. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial. EuroIntervention. 2014 Aug; 10(4):439-48.